Novartis AG ADR (NVS)vsVyne Therapeutics Inc (VYNE)
NVS
Novartis AG ADR
$157.54
-1.83%
HEALTHCARE · Cap: $288.85B
VYNE
Vyne Therapeutics Inc
$28.56
+5511.00%
HEALTHCARE · Cap: $19.07M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 12487344% more annual revenue ($56.69B vs $454,000). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VYNE
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.8%
Fair Value
$93.10
Current Price
$157.54
$64.44 premium
Intrinsic value data unavailable for VYNE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : VYNE
The strongest argument for VYNE centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VYNE
The primary concerns for VYNE are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
VYNE carries more volatility with a beta of 2.01 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 26/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Vyne Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?